Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Monoclonal antibody Sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent

Monoclonal antibody Sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent

US Patent 7915387 · Granted Mar 29, 2011

Estimated economic value: $16,178,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Epitopes2025
Anti-tumour response to modified self-epitopes2025
Anti-tumour immune responses to modified self-epitopes2022
Sialyl-di-Lewisa as expressed on glycoproteins but not glycolipids as a function2020
Anti-tumour immune responses to modified self-epitopes2020
Anti-tumour response to modified self-epitopes2019
Glycans as functional cancer targets and antibodies thereto2018
Nucleic acids encoding antibodies or portions thereof comprising a heterologous 2014
Monoclonal antibody SC104 and derivative thereof specifically binding to a sialy2013
Monoclonal antibody SC104 and derivative thereof specifically binding to a sialy2013
Binding member which binds to both lewis-Y and lewis-B haptens, and its use for 2012
Binding member which binds to both lewis-Y and lewis-B haptens, and its use for 2012